| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | kinesin binding | 1.57e-05 | 55 | 18 | 3 | GO:0019894 | |
| GeneOntologyMolecularFunction | guanyl-nucleotide exchange factor activity | 4.70e-05 | 231 | 18 | 4 | GO:0005085 | |
| GeneOntologyMolecularFunction | GTPase regulator activity | 9.47e-04 | 507 | 18 | 4 | GO:0030695 | |
| GeneOntologyMolecularFunction | nucleoside-triphosphatase regulator activity | 9.47e-04 | 507 | 18 | 4 | GO:0060589 | |
| GeneOntologyBiologicalProcess | development of secondary male sexual characteristics | 2.16e-06 | 3 | 18 | 2 | GO:0046544 | |
| GeneOntologyBiologicalProcess | taurine metabolic process | 2.58e-05 | 9 | 18 | 2 | GO:0019530 | |
| GeneOntologyBiologicalProcess | alkanesulfonate metabolic process | 2.58e-05 | 9 | 18 | 2 | GO:0019694 | |
| GeneOntologyBiologicalProcess | growth hormone receptor signaling pathway via JAK-STAT | 3.22e-05 | 10 | 18 | 2 | GO:0060397 | |
| GeneOntologyBiologicalProcess | development of secondary female sexual characteristics | 3.22e-05 | 10 | 18 | 2 | GO:0046543 | |
| GeneOntologyBiologicalProcess | negative regulation of erythrocyte differentiation | 3.94e-05 | 11 | 18 | 2 | GO:0045647 | |
| GeneOntologyBiologicalProcess | response to interleukin-2 | 3.94e-05 | 11 | 18 | 2 | GO:0070669 | |
| GeneOntologyBiologicalProcess | positive regulation of natural killer cell differentiation | 4.72e-05 | 12 | 18 | 2 | GO:0032825 | |
| GeneOntologyBiologicalProcess | response to interleukin-15 | 4.72e-05 | 12 | 18 | 2 | GO:0070672 | |
| GeneOntologyBiologicalProcess | positive regulation of gamma-delta T cell differentiation | 4.72e-05 | 12 | 18 | 2 | GO:0045588 | |
| GeneOntologyBiologicalProcess | development of secondary sexual characteristics | 5.58e-05 | 13 | 18 | 2 | GO:0045136 | |
| GeneOntologyBiologicalProcess | mucosa-associated lymphoid tissue development | 5.58e-05 | 13 | 18 | 2 | GO:0048537 | |
| GeneOntologyBiologicalProcess | Peyer's patch development | 5.58e-05 | 13 | 18 | 2 | GO:0048541 | |
| GeneOntologyBiologicalProcess | positive regulation of gamma-delta T cell activation | 6.51e-05 | 14 | 18 | 2 | GO:0046645 | |
| GeneOntologyBiologicalProcess | regulation of gamma-delta T cell differentiation | 7.50e-05 | 15 | 18 | 2 | GO:0045586 | |
| GeneOntologyBiologicalProcess | luteinization | 8.57e-05 | 16 | 18 | 2 | GO:0001553 | |
| GeneOntologyBiologicalProcess | regulation of gamma-delta T cell activation | 9.71e-05 | 17 | 18 | 2 | GO:0046643 | |
| GeneOntologyBiologicalProcess | gamma-delta T cell differentiation | 1.35e-04 | 20 | 18 | 2 | GO:0042492 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell differentiation | 1.50e-04 | 21 | 18 | 2 | GO:0032823 | |
| GeneOntologyBiologicalProcess | positive regulation of B cell differentiation | 1.50e-04 | 21 | 18 | 2 | GO:0045579 | |
| GeneOntologyBiologicalProcess | hematopoietic or lymphoid organ development | 1.99e-04 | 133 | 18 | 3 | GO:0048534 | |
| GeneOntologyBiologicalProcess | growth hormone receptor signaling pathway | 2.31e-04 | 26 | 18 | 2 | GO:0060396 | |
| GeneOntologyBiologicalProcess | cellular response to growth hormone stimulus | 2.49e-04 | 27 | 18 | 2 | GO:0071378 | |
| GeneOntologyBiologicalProcess | negative regulation of myeloid cell apoptotic process | 2.49e-04 | 27 | 18 | 2 | GO:0033033 | |
| GeneOntologyBiologicalProcess | positive regulation of activated T cell proliferation | 3.51e-04 | 32 | 18 | 2 | GO:0042104 | |
| GeneOntologyBiologicalProcess | gamma-delta T cell activation | 3.74e-04 | 33 | 18 | 2 | GO:0046629 | |
| GeneOntologyBiologicalProcess | positive regulation of natural killer cell activation | 4.21e-04 | 35 | 18 | 2 | GO:0032816 | |
| GeneOntologyBiologicalProcess | natural killer cell differentiation | 4.96e-04 | 38 | 18 | 2 | GO:0001779 | |
| GeneOntologyBiologicalProcess | positive regulation of natural killer cell mediated cytotoxicity | 5.50e-04 | 40 | 18 | 2 | GO:0045954 | |
| GeneOntologyBiologicalProcess | response to interleukin-4 | 5.78e-04 | 41 | 18 | 2 | GO:0070670 | |
| GeneOntologyBiologicalProcess | response to growth hormone | 5.78e-04 | 41 | 18 | 2 | GO:0060416 | |
| GeneOntologyBiologicalProcess | positive regulation of interleukin-2 production | 6.07e-04 | 42 | 18 | 2 | GO:0032743 | |
| GeneOntologyBiologicalProcess | regulation of myeloid cell apoptotic process | 6.07e-04 | 42 | 18 | 2 | GO:0033032 | |
| GeneOntologyBiologicalProcess | positive regulation of natural killer cell mediated immunity | 6.66e-04 | 44 | 18 | 2 | GO:0002717 | |
| GeneOntologyBiologicalProcess | regulation of B cell differentiation | 7.28e-04 | 46 | 18 | 2 | GO:0045577 | |
| GeneOntologyBiologicalProcess | positive regulation of multicellular organism growth | 7.60e-04 | 47 | 18 | 2 | GO:0040018 | |
| GeneOntologyBiologicalProcess | lactation | 7.92e-04 | 48 | 18 | 2 | GO:0007595 | |
| GeneOntologyBiologicalProcess | regulation of epithelial cell differentiation | 8.34e-04 | 217 | 18 | 3 | GO:0030856 | |
| GeneOntologyBiologicalProcess | myeloid cell apoptotic process | 8.94e-04 | 51 | 18 | 2 | GO:0033028 | |
| GeneOntologyBiologicalProcess | clathrin-dependent endocytosis | 9.65e-04 | 53 | 18 | 2 | GO:0072583 | |
| GeneOntologyBiologicalProcess | regulation of activated T cell proliferation | 1.00e-03 | 54 | 18 | 2 | GO:0046006 | |
| GeneOntologyBiologicalProcess | small GTPase-mediated signal transduction | 1.05e-03 | 538 | 18 | 4 | GO:0007264 | |
| GeneOntologyBiologicalProcess | T cell homeostasis | 1.19e-03 | 59 | 18 | 2 | GO:0043029 | |
| GeneOntologyBiologicalProcess | immune system development | 1.23e-03 | 248 | 18 | 3 | GO:0002520 | |
| GeneOntologyBiologicalProcess | regulation of erythrocyte differentiation | 1.24e-03 | 60 | 18 | 2 | GO:0045646 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell activation | 1.28e-03 | 61 | 18 | 2 | GO:0032814 | |
| GeneOntologyBiologicalProcess | activated T cell proliferation | 1.45e-03 | 65 | 18 | 2 | GO:0050798 | |
| GeneOntologyBiologicalProcess | positive regulation of defense response | 1.46e-03 | 589 | 18 | 4 | GO:0031349 | |
| GeneOntologyBiologicalProcess | ovulation cycle process | 1.58e-03 | 68 | 18 | 2 | GO:0022602 | |
| GeneOntologyBiologicalProcess | regulation of interleukin-2 production | 1.87e-03 | 74 | 18 | 2 | GO:0032663 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity | 1.97e-03 | 76 | 18 | 2 | GO:0042269 | |
| GeneOntologyBiologicalProcess | positive regulation of leukocyte mediated cytotoxicity | 2.13e-03 | 79 | 18 | 2 | GO:0001912 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immunity | 2.18e-03 | 80 | 18 | 2 | GO:0002715 | |
| GeneOntologyBiologicalProcess | interleukin-2 production | 2.29e-03 | 82 | 18 | 2 | GO:0032623 | |
| GeneOntologyBiologicalProcess | positive regulation of cell killing | 2.63e-03 | 88 | 18 | 2 | GO:0031343 | |
| GeneOntologyBiologicalProcess | regulation of small GTPase mediated signal transduction | 2.84e-03 | 333 | 18 | 3 | GO:0051056 | |
| GeneOntologyBiologicalProcess | regulation of multicellular organism growth | 2.94e-03 | 93 | 18 | 2 | GO:0040014 | |
| GeneOntologyBiologicalProcess | ovulation cycle | 3.06e-03 | 95 | 18 | 2 | GO:0042698 | |
| GeneOntologyBiologicalProcess | axo-dendritic transport | 3.25e-03 | 98 | 18 | 2 | GO:0008088 | |
| GeneOntologyBiologicalProcess | positive regulation of B cell activation | 3.38e-03 | 100 | 18 | 2 | GO:0050871 | |
| GeneOntologyBiologicalProcess | rhythmic process | 3.54e-03 | 360 | 18 | 3 | GO:0048511 | |
| GeneOntologyBiologicalProcess | lymphocyte homeostasis | 3.65e-03 | 104 | 18 | 2 | GO:0002260 | |
| GeneOntologyBiologicalProcess | lipid storage | 3.72e-03 | 105 | 18 | 2 | GO:0019915 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated cytotoxicity | 3.72e-03 | 105 | 18 | 2 | GO:0042267 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated immunity | 4.01e-03 | 109 | 18 | 2 | GO:0002228 | |
| GeneOntologyBiologicalProcess | T cell differentiation in thymus | 4.37e-03 | 114 | 18 | 2 | GO:0033077 | |
| GeneOntologyBiologicalProcess | body fluid secretion | 4.91e-03 | 121 | 18 | 2 | GO:0007589 | |
| GeneOntologyBiologicalProcess | positive regulation of cell cycle | 4.99e-03 | 407 | 18 | 3 | GO:0045787 | |
| GeneOntologyBiologicalProcess | regulation of leukocyte mediated cytotoxicity | 5.15e-03 | 124 | 18 | 2 | GO:0001910 | |
| GeneOntologyBiologicalProcess | natural killer cell activation | 5.15e-03 | 124 | 18 | 2 | GO:0030101 | |
| GeneOntologyBiologicalProcess | positive regulation of T cell proliferation | 5.23e-03 | 125 | 18 | 2 | GO:0042102 | |
| GeneOntologyBiologicalProcess | positive regulation of innate immune response | 5.45e-03 | 420 | 18 | 3 | GO:0045089 | |
| GeneOntologyBiologicalProcess | negative regulation of myeloid cell differentiation | 5.99e-03 | 134 | 18 | 2 | GO:0045638 | |
| GeneOntologyBiologicalProcess | positive regulation of myeloid cell differentiation | 5.99e-03 | 134 | 18 | 2 | GO:0045639 | |
| GeneOntologyBiologicalProcess | regulation of steroid metabolic process | 6.07e-03 | 135 | 18 | 2 | GO:0019218 | |
| GeneOntologyCellularComponent | kinesin complex | 9.63e-06 | 49 | 18 | 3 | GO:0005871 | |
| GeneOntologyCellularComponent | ciliary rootlet | 8.34e-05 | 16 | 18 | 2 | GO:0035253 | |
| GeneOntologyCellularComponent | microtubule associated complex | 3.36e-04 | 161 | 18 | 3 | GO:0005875 | |
| GeneOntologyCellularComponent | microtubule | 9.62e-04 | 533 | 18 | 4 | GO:0005874 | |
| GeneOntologyCellularComponent | RNA polymerase II transcription regulator complex | 1.54e-03 | 272 | 18 | 3 | GO:0090575 | |
| GeneOntologyCellularComponent | polymeric cytoskeletal fiber | 6.42e-03 | 899 | 18 | 4 | GO:0099513 | |
| HumanPheno | Metrorrhagia | 5.53e-05 | 16 | 4 | 2 | HP:0100608 | |
| HumanPheno | Diffuse alveolar hemorrhage | 6.27e-05 | 17 | 4 | 2 | HP:0025420 | |
| HumanPheno | Oral cavity bleeding | 9.67e-05 | 21 | 4 | 2 | HP:0030140 | |
| HumanPheno | Chronic infection | 1.16e-04 | 23 | 4 | 2 | HP:0031035 | |
| HumanPheno | Problematic alcohol consumption | 1.61e-04 | 27 | 4 | 2 | HP:5200329 | |
| HumanPheno | Addictive alcohol use | 1.61e-04 | 27 | 4 | 2 | HP:0030955 | |
| HumanPheno | Addictive behavior | 1.61e-04 | 27 | 4 | 2 | HP:0030858 | |
| HumanPheno | Abnormal alcohol consumption | 1.61e-04 | 27 | 4 | 2 | HP:0430037 | |
| HumanPheno | Bone marrow hypercellularity | 1.74e-04 | 28 | 4 | 2 | HP:0031020 | |
| HumanPheno | Disseminated intravascular coagulation | 1.86e-04 | 29 | 4 | 2 | HP:0005521 | |
| HumanPheno | Pulmonary hemorrhage | 2.13e-04 | 31 | 4 | 2 | HP:0040223 | |
| HumanPheno | Hypofibrinogenemia | 3.94e-04 | 42 | 4 | 2 | HP:0011900 | |
| HumanPheno | Abnormality of circulating fibrinogen | 5.15e-04 | 48 | 4 | 2 | HP:0011898 | |
| HumanPheno | Gangrene | 7.02e-04 | 56 | 4 | 2 | HP:0100758 | |
| HumanPheno | Ecchymosis | 7.53e-04 | 58 | 4 | 2 | HP:0031364 | |
| HumanPheno | Oral bleeding | 8.06e-04 | 60 | 4 | 2 | HP:0000167 | |
| HumanPheno | Gingival bleeding | 8.06e-04 | 60 | 4 | 2 | HP:0000225 | |
| HumanPheno | Petechiae | 8.89e-04 | 63 | 4 | 2 | HP:0000967 | |
| HumanPheno | Irregular menstruation | 1.02e-03 | 329 | 4 | 3 | HP:0000858 | |
| HumanPheno | Abnormality of the menstrual cycle | 1.02e-03 | 329 | 4 | 3 | HP:0000140 | |
| HumanPheno | Abnormality of the common coagulation pathway | 1.04e-03 | 68 | 4 | 2 | HP:0010990 | |
| HumanPheno | Productive cough | 1.04e-03 | 68 | 4 | 2 | HP:0031245 | |
| HumanPheno | Stomatitis | 1.10e-03 | 70 | 4 | 2 | HP:0010280 | |
| HumanPheno | Abnormal drinking behavior | 1.47e-03 | 81 | 4 | 2 | HP:0030082 | |
| HumanPheno | Bone pain | 1.69e-03 | 87 | 4 | 2 | HP:0002653 | |
| HumanPheno | Abnormal female reproductive system physiology | 1.76e-03 | 396 | 4 | 3 | HP:0030012 | |
| HumanPheno | Macular purpura | 1.77e-03 | 89 | 4 | 2 | HP:0031365 | |
| HumanPheno | Epistaxis | 2.60e-03 | 108 | 4 | 2 | HP:0000421 | |
| HumanPheno | Anorexia | 3.42e-03 | 124 | 4 | 2 | HP:0002039 | |
| HumanPheno | Fatigue | 3.49e-03 | 500 | 4 | 3 | HP:0012378 | |
| HumanPheno | Gingival overgrowth | 3.53e-03 | 126 | 4 | 2 | HP:0000212 | |
| HumanPheno | Pancytopenia | 3.69e-03 | 129 | 4 | 2 | HP:0001876 | |
| HumanPheno | Cellular metachromasia | 3.81e-03 | 131 | 4 | 2 | HP:0003653 | |
| HumanPheno | Purpura | 3.86e-03 | 132 | 4 | 2 | HP:0000979 | |
| HumanPheno | Vertigo | 4.71e-03 | 146 | 4 | 2 | HP:0002321 | |
| HumanPheno | Exertional dyspnea | 4.78e-03 | 147 | 4 | 2 | HP:0002875 | |
| HumanPheno | Abnormality of glycosaminoglycan metabolism | 5.10e-03 | 152 | 4 | 2 | HP:0004371 | |
| HumanPheno | Abnormality of mucopolysaccharide metabolism | 5.10e-03 | 152 | 4 | 2 | HP:0011020 | |
| HumanPheno | Abnormal circulating polysaccharide concentration | 5.10e-03 | 152 | 4 | 2 | HP:0011012 | |
| HumanPheno | Leukocytosis | 5.57e-03 | 159 | 4 | 2 | HP:0001974 | |
| HumanPheno | Cough | 5.64e-03 | 160 | 4 | 2 | HP:0012735 | |
| HumanPheno | Abnormality of the coagulation cascade | 5.71e-03 | 161 | 4 | 2 | HP:0003256 | |
| Domain | Kinesin_light_repeat | 6.26e-10 | 3 | 17 | 3 | IPR015792 | |
| Domain | KINESIN_LIGHT | 6.26e-10 | 3 | 17 | 3 | PS01160 | |
| Domain | Kinesin_light | 2.50e-09 | 4 | 17 | 3 | IPR002151 | |
| Domain | Rabaptin_Rab5-bd_dom | 1.25e-08 | 6 | 17 | 3 | IPR015390 | |
| Domain | TPR_10 | 1.25e-08 | 6 | 17 | 3 | PF13374 | |
| Domain | Rab5-bind | 1.25e-08 | 6 | 17 | 3 | PF09311 | |
| Domain | STAT_TF_prot_interaction | 1.63e-05 | 7 | 17 | 2 | IPR013799 | |
| Domain | STAT_TF_DNA-bd_sub | 1.63e-05 | 7 | 17 | 2 | IPR012345 | |
| Domain | STAT | 1.63e-05 | 7 | 17 | 2 | IPR001217 | |
| Domain | STAT_TF_coiled-coil | 1.63e-05 | 7 | 17 | 2 | IPR015988 | |
| Domain | STAT_int | 1.63e-05 | 7 | 17 | 2 | SM00964 | |
| Domain | - | 1.63e-05 | 7 | 17 | 2 | 2.60.40.630 | |
| Domain | - | 1.63e-05 | 7 | 17 | 2 | 1.10.532.10 | |
| Domain | STAT_TF_DNA-bd | 1.63e-05 | 7 | 17 | 2 | IPR013801 | |
| Domain | STAT_bind | 1.63e-05 | 7 | 17 | 2 | PF02864 | |
| Domain | STAT_alpha | 1.63e-05 | 7 | 17 | 2 | PF01017 | |
| Domain | STAT_int | 1.63e-05 | 7 | 17 | 2 | PF02865 | |
| Domain | - | 1.63e-05 | 7 | 17 | 2 | 1.20.1050.20 | |
| Domain | STAT_TF_alpha | 2.18e-05 | 8 | 17 | 2 | IPR013800 | |
| Domain | DH_1 | 2.40e-05 | 63 | 17 | 3 | PS00741 | |
| Domain | DH_2 | 3.30e-05 | 70 | 17 | 3 | PS50010 | |
| Domain | RhoGEF | 3.30e-05 | 70 | 17 | 3 | PF00621 | |
| Domain | - | 3.45e-05 | 71 | 17 | 3 | 1.20.900.10 | |
| Domain | DH-domain | 3.45e-05 | 71 | 17 | 3 | IPR000219 | |
| Domain | TPR_1 | 7.01e-05 | 90 | 17 | 3 | PF00515 | |
| Domain | TPR_1 | 7.01e-05 | 90 | 17 | 3 | IPR001440 | |
| Domain | Pentatricopeptide_repeat | 1.95e-04 | 23 | 17 | 2 | IPR002885 | |
| Domain | TPR | 2.04e-04 | 129 | 17 | 3 | SM00028 | |
| Domain | TPR_repeat | 2.23e-04 | 133 | 17 | 3 | IPR019734 | |
| Domain | TPR-contain_dom | 3.18e-04 | 150 | 17 | 3 | IPR013026 | |
| Domain | TPR | 4.20e-04 | 165 | 17 | 3 | PS50005 | |
| Domain | TPR_REGION | 4.20e-04 | 165 | 17 | 3 | PS50293 | |
| Domain | - | 8.14e-04 | 207 | 17 | 3 | 1.25.40.10 | |
| Domain | p53-like_TF_DNA-bd | 1.05e-03 | 53 | 17 | 2 | IPR008967 | |
| Domain | TPR-like_helical_dom | 1.15e-03 | 233 | 17 | 3 | IPR011990 | |
| Domain | - | 1.59e-03 | 261 | 17 | 3 | 1.10.238.10 | |
| Domain | RhoGEF | 1.71e-03 | 68 | 17 | 2 | SM00325 | |
| Domain | PH | 1.90e-03 | 278 | 17 | 3 | SM00233 | |
| Domain | PH_DOMAIN | 1.92e-03 | 279 | 17 | 3 | PS50003 | |
| Domain | PH_domain | 1.94e-03 | 280 | 17 | 3 | IPR001849 | |
| Domain | EF-hand-dom_pair | 2.08e-03 | 287 | 17 | 3 | IPR011992 | |
| Domain | SH2 | 3.73e-03 | 101 | 17 | 2 | PF00017 | |
| Domain | SH2 | 4.41e-03 | 110 | 17 | 2 | SM00252 | |
| Domain | SH2 | 4.49e-03 | 111 | 17 | 2 | PS50001 | |
| Domain | SH2 | 4.57e-03 | 112 | 17 | 2 | IPR000980 | |
| Domain | - | 4.57e-03 | 112 | 17 | 2 | 3.30.505.10 | |
| Domain | - | 4.98e-03 | 391 | 17 | 3 | 2.30.29.30 | |
| Domain | PH_dom-like | 6.32e-03 | 426 | 17 | 3 | IPR011993 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_PSEN1_TO_ANTEROGRADE_AXONAL_TRANSPORT | 8.16e-08 | 9 | 15 | 3 | M47699 | |
| Pathway | REACTOME_RHO_GTPASES_ACTIVATE_KTN1 | 1.60e-07 | 11 | 15 | 3 | MM15218 | |
| Pathway | REACTOME_RHO_GTPASES_ACTIVATE_KTN1 | 1.60e-07 | 11 | 15 | 3 | M27490 | |
| Pathway | KEGG_MEDICUS_VARIANT_OLIGOMERIC_CONFORMATION_PRPC_TO_ANTEROGRADE_AXONAL_TRANSPORT | 2.77e-07 | 13 | 15 | 3 | M47763 | |
| Pathway | KEGG_MEDICUS_REFERENCE_ANTEROGRADE_AXONAL_TRANSPORT | 1.95e-06 | 24 | 15 | 3 | M47671 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_SALMONELLA_SIFA_TO_MICROTUBULE_PLUS_END_DIRECTED_TRANSPORT | 2.21e-06 | 25 | 15 | 3 | M47775 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_SNCA_TO_ANTEROGRADE_AXONAL_TRANSPORT | 2.21e-06 | 25 | 15 | 3 | M47710 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_HTT_TO_ANTEROGRADE_AXONAL_TRANSPORT | 2.50e-06 | 26 | 15 | 3 | M47672 | |
| Pathway | KEGG_MEDICUS_REFERENCE_ARL8_REGULATED_MICROTUBULE_PLUS_END_DIRECTED_TRANSPORT | 6.25e-06 | 35 | 15 | 3 | M47774 | |
| Pathway | KEGG_MEDICUS_VARIANT_EML4_ALK_FUSION_KINASE_TO_JAK_STAT_SIGNALING_PATHWAY | 1.05e-05 | 5 | 15 | 2 | M48987 | |
| Pathway | KEGG_MEDICUS_VARIANT_DUPLICATION_OR_MUTATION_ACTIVATED_FLT3_TO_JAK_STAT_SIGNALING_PATHWAY | 1.05e-05 | 5 | 15 | 2 | M48986 | |
| Pathway | KEGG_MEDICUS_REFERENCE_PRL_JAK_STAT_SIGNALING_PATHWAY | 1.05e-05 | 5 | 15 | 2 | M49006 | |
| Pathway | REACTOME_INTERLEUKIN_9_SIGNALING | 1.58e-05 | 6 | 15 | 2 | MM15581 | |
| Pathway | REACTOME_INTERLEUKIN_21_SIGNALING | 1.58e-05 | 6 | 15 | 2 | MM15621 | |
| Pathway | KEGG_MEDICUS_REFERENCE_GH_JAK_STAT_SIGNALING_PATHWAY | 2.21e-05 | 7 | 15 | 2 | M47646 | |
| Pathway | REACTOME_STAT5_ACTIVATION | 2.21e-05 | 7 | 15 | 2 | M27953 | |
| Pathway | REACTOME_ERYTHROPOIETIN_ACTIVATES_STAT5 | 2.21e-05 | 7 | 15 | 2 | M27907 | |
| Pathway | KEGG_MEDICUS_REFERENCE_EGF_JAK_STAT_SIGNALING_PATHWAY | 2.21e-05 | 7 | 15 | 2 | M47430 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_HTLV_1_P12_TO_JAK_STAT_SIGNALING_PATHWAY | 2.21e-05 | 7 | 15 | 2 | M47581 | |
| Pathway | REACTOME_KINESINS | 2.76e-05 | 57 | 15 | 3 | MM15714 | |
| Pathway | REACTOME_KINESINS | 3.38e-05 | 61 | 15 | 3 | M977 | |
| Pathway | REACTOME_INTERLEUKIN_9_SIGNALING | 3.79e-05 | 9 | 15 | 2 | M27861 | |
| Pathway | BIOCARTA_IL22BP_PATHWAY | 3.79e-05 | 9 | 15 | 2 | MM1419 | |
| Pathway | BIOCARTA_IL22BP_PATHWAY | 3.79e-05 | 9 | 15 | 2 | M8066 | |
| Pathway | REACTOME_INTERLEUKIN_21_SIGNALING | 4.73e-05 | 10 | 15 | 2 | M27898 | |
| Pathway | REACTOME_STAT5_ACTIVATION_DOWNSTREAM_OF_FLT3_ITD_MUTANTS | 4.73e-05 | 10 | 15 | 2 | M41731 | |
| Pathway | REACTOME_INTERLEUKIN_2_SIGNALING | 4.73e-05 | 10 | 15 | 2 | MM15618 | |
| Pathway | REACTOME_SIGNALING_BY_LEPTIN | 5.78e-05 | 11 | 15 | 2 | M27195 | |
| Pathway | REACTOME_INTERLEUKIN_15_SIGNALING | 5.78e-05 | 11 | 15 | 2 | MM15578 | |
| Pathway | REACTOME_SIGNALING_BY_RHO_GTPASES_MIRO_GTPASES_AND_RHOBTB3 | 5.85e-05 | 720 | 15 | 6 | M41838 | |
| Pathway | REACTOME_INTERLEUKIN_2_SIGNALING | 6.93e-05 | 12 | 15 | 2 | M27893 | |
| Pathway | REACTOME_INTERLEUKIN_15_SIGNALING | 9.55e-05 | 14 | 15 | 2 | M27858 | |
| Pathway | PID_IL5_PATHWAY | 9.55e-05 | 14 | 15 | 2 | M135 | |
| Pathway | REACTOME_PROLACTIN_RECEPTOR_SIGNALING | 1.10e-04 | 15 | 15 | 2 | M552 | |
| Pathway | BIOCARTA_IL3_PATHWAY | 1.10e-04 | 15 | 15 | 2 | MM1412 | |
| Pathway | BIOCARTA_IL3_PATHWAY | 1.10e-04 | 15 | 15 | 2 | M17681 | |
| Pathway | WP_FOXP3_IN_COVID19 | 1.10e-04 | 15 | 15 | 2 | M42573 | |
| Pathway | REACTOME_INTERLEUKIN_7_SIGNALING | 1.10e-04 | 15 | 15 | 2 | MM14536 | |
| Pathway | BIOCARTA_IL7_PATHWAY | 1.26e-04 | 16 | 15 | 2 | M1296 | |
| Pathway | BIOCARTA_IL7_PATHWAY | 1.26e-04 | 16 | 15 | 2 | MM1420 | |
| Pathway | REACTOME_SIGNALING_BY_FLT3_ITD_AND_TKD_MUTANTS | 1.26e-04 | 16 | 15 | 2 | M41733 | |
| Pathway | REACTOME_GROWTH_HORMONE_RECEPTOR_SIGNALING | 1.26e-04 | 16 | 15 | 2 | MM15710 | |
| Pathway | REACTOME_COPI_DEPENDENT_GOLGI_TO_ER_RETROGRADE_TRAFFIC | 1.40e-04 | 98 | 15 | 3 | MM15352 | |
| Pathway | WP_IL9_SIGNALING | 1.42e-04 | 17 | 15 | 2 | M39644 | |
| Pathway | KEGG_MEDICUS_REFERENCE_HORMONE_LIKE_CYTOKINE_TO_JAK_STAT_SIGNALING_PATHWAY | 1.42e-04 | 17 | 15 | 2 | M47905 | |
| Pathway | REACTOME_COPI_DEPENDENT_GOLGI_TO_ER_RETROGRADE_TRAFFIC | 1.48e-04 | 100 | 15 | 3 | M27650 | |
| Pathway | REACTOME_SIGNALING_BY_CYTOSOLIC_FGFR1_FUSION_MUTANTS | 1.60e-04 | 18 | 15 | 2 | M673 | |
| Pathway | BIOCARTA_EPO_PATHWAY | 1.79e-04 | 19 | 15 | 2 | M12836 | |
| Pathway | REACTOME_SIGNALING_BY_FLT3_FUSION_PROTEINS | 1.79e-04 | 19 | 15 | 2 | M41732 | |
| Pathway | REACTOME_INTERLEUKIN_20_FAMILY_SIGNALING | 1.99e-04 | 20 | 15 | 2 | MM15496 | |
| Pathway | BIOCARTA_EPO_PATHWAY | 1.99e-04 | 20 | 15 | 2 | MM1389 | |
| Pathway | REACTOME_SIGNALING_BY_KIT_IN_DISEASE | 1.99e-04 | 20 | 15 | 2 | M39002 | |
| Pathway | REACTOME_MHC_CLASS_II_ANTIGEN_PRESENTATION | 2.30e-04 | 116 | 15 | 3 | MM14855 | |
| Pathway | REACTOME_FACTORS_INVOLVED_IN_MEGAKARYOCYTE_DEVELOPMENT_AND_PLATELET_PRODUCTION | 2.30e-04 | 116 | 15 | 3 | MM15715 | |
| Pathway | BIOCARTA_IL2_PATHWAY | 2.41e-04 | 22 | 15 | 2 | M7747 | |
| Pathway | BIOCARTA_IL2_PATHWAY | 2.64e-04 | 23 | 15 | 2 | MM1411 | |
| Pathway | BIOCARTA_GLEEVEC_PATHWAY | 2.64e-04 | 23 | 15 | 2 | MM1424 | |
| Pathway | KEGG_MEDICUS_REFERENCE_IL2_FAMILY_TO_JAK_STAT_SIGNALING_PATHWAY | 2.64e-04 | 23 | 15 | 2 | M47904 | |
| Pathway | BIOCARTA_GLEEVEC_PATHWAY | 2.64e-04 | 23 | 15 | 2 | M7897 | |
| Pathway | BIOCARTA_TPO_PATHWAY | 2.88e-04 | 24 | 15 | 2 | M11520 | |
| Pathway | REACTOME_GROWTH_HORMONE_RECEPTOR_SIGNALING | 2.88e-04 | 24 | 15 | 2 | M519 | |
| Pathway | REACTOME_MHC_CLASS_II_ANTIGEN_PRESENTATION | 2.93e-04 | 126 | 15 | 3 | M705 | |
| Pathway | REACTOME_SIGNALING_BY_ERYTHROPOIETIN | 3.13e-04 | 25 | 15 | 2 | M27865 | |
| Pathway | REACTOME_INACTIVATION_OF_CSF3_G_CSF_SIGNALING | 3.13e-04 | 25 | 15 | 2 | M41829 | |
| Pathway | BIOCARTA_TPO_PATHWAY | 3.13e-04 | 25 | 15 | 2 | MM1519 | |
| Pathway | WP_IL7_SIGNALING | 3.13e-04 | 25 | 15 | 2 | M39499 | |
| Pathway | REACTOME_GOLGI_TO_ER_RETROGRADE_TRANSPORT | 3.29e-04 | 131 | 15 | 3 | MM15497 | |
| Pathway | WP_EPO_RECEPTOR_SIGNALING | 3.38e-04 | 26 | 15 | 2 | M39687 | |
| Pathway | REACTOME_INTERLEUKIN_20_FAMILY_SIGNALING | 3.38e-04 | 26 | 15 | 2 | M27750 | |
| Pathway | PID_IL3_PATHWAY | 3.38e-04 | 26 | 15 | 2 | M182 | |
| Pathway | WP_EPO_RECEPTOR_SIGNALING | 3.38e-04 | 26 | 15 | 2 | MM15896 | |
| Pathway | REACTOME_GOLGI_TO_ER_RETROGRADE_TRANSPORT | 3.51e-04 | 134 | 15 | 3 | M27751 | |
| Pathway | REACTOME_DOWNSTREAM_SIGNAL_TRANSDUCTION | 3.65e-04 | 27 | 15 | 2 | MM14712 | |
| Pathway | BIOCARTA_GH_PATHWAY | 3.65e-04 | 27 | 15 | 2 | M9043 | |
| Pathway | REACTOME_FLT3_SIGNALING_IN_DISEASE | 3.93e-04 | 28 | 15 | 2 | M41724 | |
| Pathway | REACTOME_SIGNALING_BY_RHO_GTPASES_MIRO_GTPASES_AND_RHOBTB3 | 4.16e-04 | 649 | 15 | 5 | MM15690 | |
| Pathway | WP_PDGFRBETA_PATHWAY | 4.22e-04 | 29 | 15 | 2 | M39616 | |
| Pathway | REACTOME_DOWNSTREAM_SIGNAL_TRANSDUCTION | 4.22e-04 | 29 | 15 | 2 | M779 | |
| Pathway | REACTOME_SIGNALING_BY_CSF3_G_CSF | 4.52e-04 | 30 | 15 | 2 | M41825 | |
| Pathway | PID_IL2_STAT5_PATHWAY | 4.52e-04 | 30 | 15 | 2 | M234 | |
| Pathway | REACTOME_FGFR1_MUTANT_RECEPTOR_ACTIVATION | 4.83e-04 | 31 | 15 | 2 | M661 | |
| Pathway | WP_WHITE_FAT_CELL_DIFFERENTIATION | 5.15e-04 | 32 | 15 | 2 | M39333 | |
| Pathway | WP_WHITE_FAT_CELL_DIFFERENTIATION | 5.47e-04 | 33 | 15 | 2 | MM15869 | |
| Pathway | BIOCARTA_GH_PATHWAY | 5.47e-04 | 33 | 15 | 2 | MM1404 | |
| Pathway | PID_EPO_PATHWAY | 5.47e-04 | 33 | 15 | 2 | M233 | |
| Pathway | WP_JAKSTAT_SIGNALING_IN_THE_REGULATION_OF_BETA_CELLS | 5.81e-04 | 34 | 15 | 2 | M48081 | |
| Pathway | REACTOME_INTERLEUKIN_2_FAMILY_SIGNALING | 6.16e-04 | 35 | 15 | 2 | MM15144 | |
| Pathway | REACTOME_INTERLEUKIN_7_SIGNALING | 6.52e-04 | 36 | 15 | 2 | M542 | |
| Pathway | BIOCARTA_IL2RB_PATHWAY | 6.52e-04 | 36 | 15 | 2 | MM1418 | |
| Pathway | PID_GMCSF_PATHWAY | 6.52e-04 | 36 | 15 | 2 | M22 | |
| Pathway | REACTOME_SIGNALING_BY_SCF_KIT | 6.89e-04 | 37 | 15 | 2 | MM14564 | |
| Pathway | BIOCARTA_IL2RB_PATHWAY | 6.89e-04 | 37 | 15 | 2 | M8615 | |
| Pathway | REACTOME_EPHB_MEDIATED_FORWARD_SIGNALING | 6.89e-04 | 37 | 15 | 2 | MM15022 | |
| Pathway | REACTOME_FACTORS_INVOLVED_IN_MEGAKARYOCYTE_DEVELOPMENT_AND_PLATELET_PRODUCTION | 7.05e-04 | 170 | 15 | 3 | M941 | |
| Pathway | REACTOME_FLT3_SIGNALING | 7.27e-04 | 38 | 15 | 2 | M29803 | |
| Pathway | REACTOME_SIGNALING_BY_FGFR1_IN_DISEASE | 7.27e-04 | 38 | 15 | 2 | M27536 | |
| Pathway | PID_ERBB4_PATHWAY | 7.27e-04 | 38 | 15 | 2 | M13 | |
| Pathway | WP_IL5_SIGNALING | 8.05e-04 | 40 | 15 | 2 | M39392 | |
| Pathway | REACTOME_INTERLEUKIN_3_INTERLEUKIN_5_AND_GM_CSF_SIGNALING | 8.46e-04 | 41 | 15 | 2 | MM15162 | |
| Pathway | PID_TCPTP_PATHWAY | 8.88e-04 | 42 | 15 | 2 | M91 | |
| Pubmed | 2.55e-08 | 12 | 18 | 3 | 16018997 | ||
| Pubmed | 1.09e-07 | 87 | 18 | 4 | 17979178 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 9852045 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 23275557 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 31599926 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 23151802 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 28500076 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 26999798 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 21826656 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 19966185 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 21704724 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 10594041 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 21036145 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 11867689 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 10486277 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 7720707 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 27367207 | ||
| Pubmed | Global analysis of IL-2 target genes: identification of chromosomal clusters of expressed genes. | 2.53e-07 | 2 | 18 | 2 | 15980098 | |
| Pubmed | Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. | 2.53e-07 | 2 | 18 | 2 | 20233708 | |
| Pubmed | STAT5A and STAT5B have opposite correlations with drug response gene expression. | 2.53e-07 | 2 | 18 | 2 | 27264955 | |
| Pubmed | Involvement of the STAT5 signaling pathway in the regulation of mouse preimplantation development. | 2.53e-07 | 2 | 18 | 2 | 16775227 | |
| Pubmed | Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. | 2.53e-07 | 2 | 18 | 2 | 16493008 | |
| Pubmed | A Mouse Model to Assess STAT3 and STAT5A/B Combined Inhibition in Health and Disease Conditions. | 2.53e-07 | 2 | 18 | 2 | 31443474 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 17447893 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 24335105 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 38618957 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 15340066 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 8816482 | ||
| Pubmed | Brain STAT5 signaling modulates learning and memory formation. | 2.53e-07 | 2 | 18 | 2 | 29460051 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 12377952 | ||
| Pubmed | Identification of human STAT5-dependent gene regulatory elements based on interspecies homology. | 2.53e-07 | 2 | 18 | 2 | 16840779 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 10851057 | ||
| Pubmed | Genome-wide regulation of electro-acupuncture on the neural Stat5-loss-induced obese mice. | 2.53e-07 | 2 | 18 | 2 | 28806763 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 22159083 | ||
| Pubmed | The role of the STAT5 proteins in the proliferation and apoptosis of the CML and AML cells. | 2.53e-07 | 2 | 18 | 2 | 15128421 | |
| Pubmed | Critical functions for STAT5 tetramers in the maturation and survival of natural killer cells. | 2.53e-07 | 2 | 18 | 2 | 29105654 | |
| Pubmed | STAT5 deficiency in hepatocytes reduces diethylnitrosamine-induced liver tumorigenesis in mice. | 2.53e-07 | 2 | 18 | 2 | 30377054 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 23565285 | ||
| Pubmed | Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. | 2.53e-07 | 2 | 18 | 2 | 32790723 | |
| Pubmed | Characterization and cloning of STAT5 from IM-9 cells and its activation by growth hormone. | 2.53e-07 | 2 | 18 | 2 | 8732682 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 18492722 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 17003334 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 26717567 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 10066807 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 20008792 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 10835485 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 17438530 | ||
| Pubmed | Structural plasticity of the N-terminal capping helix of the TPR domain of kinesin light chain. | 2.53e-07 | 2 | 18 | 2 | 29036226 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 35464049 | ||
| Pubmed | Differential STAT5 signaling by ligand-dependent and constitutively active cytokine receptors. | 2.53e-07 | 2 | 18 | 2 | 15677477 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 16757175 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 15677453 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 33199496 | ||
| Pubmed | The neonatal microenvironment programs innate γδ T cells through the transcription factor STAT5. | 2.53e-07 | 2 | 18 | 2 | 32281944 | |
| Pubmed | Haploinsufficiency identifies STAT5 as a modifier of IL-7-induced lymphomas. | 2.53e-07 | 2 | 18 | 2 | 15870688 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 28606561 | ||
| Pubmed | Development of mammary luminal progenitor cells is controlled by the transcription factor STAT5A. | 2.53e-07 | 2 | 18 | 2 | 19833766 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 17317776 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 18286195 | ||
| Pubmed | STAT5A/B gene locus undergoes amplification during human prostate cancer progression. | 2.53e-07 | 2 | 18 | 2 | 23660011 | |
| Pubmed | A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. | 2.53e-07 | 2 | 18 | 2 | 21127177 | |
| Pubmed | Differentiating the roles of STAT5B and STAT5A in human CD4+ T cells. | 2.53e-07 | 2 | 18 | 2 | 23773921 | |
| Pubmed | Role of Stat5 in type I interferon-signaling and transcriptional regulation. | 2.53e-07 | 2 | 18 | 2 | 12901872 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 16289657 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 8631883 | ||
| Pubmed | Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. | 2.53e-07 | 2 | 18 | 2 | 11030348 | |
| Pubmed | Association between STAT5 polymorphisms and glioblastoma risk in Han Chinese population. | 2.53e-07 | 2 | 18 | 2 | 24878107 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 25552366 | ||
| Pubmed | Deregulation of STAT-5 isoforms in the development of HPV-mediated cervical carcinogenesis. | 2.53e-07 | 2 | 18 | 2 | 20415542 | |
| Pubmed | Adipocyte STAT5 deficiency does not affect blood glucose homeostasis in obese mice. | 2.53e-07 | 2 | 18 | 2 | 34818373 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 23332799 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 22470497 | ||
| Pubmed | Cell intrinsic defects in cytokine responsiveness of STAT5-deficient hematopoietic stem cells. | 2.53e-07 | 2 | 18 | 2 | 12393407 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 12847485 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 25470773 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 12835478 | ||
| Pubmed | [Effect of STAT5 gene silencing on the proliferation of T lymphocytes in a mouse model of asthma]. | 2.53e-07 | 2 | 18 | 2 | 22455944 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 7568026 | ||
| Pubmed | Identification of STAT5A and STAT5B target genes in human T cells. | 2.53e-07 | 2 | 18 | 2 | 24497979 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 12039059 | ||
| Pubmed | The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients. | 2.53e-07 | 2 | 18 | 2 | 32041920 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 28074064 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 23465551 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 11756158 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 36755813 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 17536022 | ||
| Pubmed | STAT5 transcriptional activity is impaired by LIF in a mammary epithelial cell line. | 2.53e-07 | 2 | 18 | 2 | 17382296 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 17976521 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 25896118 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 16502315 | ||
| Pubmed | STAT5 is essential for Akt/p70S6 kinase activity during IL-2-induced lymphocyte proliferation. | 2.53e-07 | 2 | 18 | 2 | 17911616 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 22319210 | ||
| Pubmed | STAT5 signaling in sexually dimorphic gene expression and growth patterns. | 2.53e-07 | 2 | 18 | 2 | 10486314 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 17599554 | ||
| Pubmed | Constitutively active Stat5A and Stat5B promote adipogenesis. | 2.53e-07 | 2 | 18 | 2 | 21431790 | |
| Pubmed | MiR-21 is under control of STAT5 but is dispensable for mammary development and lactation. | 2.53e-07 | 2 | 18 | 2 | 24497923 | |
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 12217382 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 25333863 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 10428030 | ||
| Pubmed | 2.53e-07 | 2 | 18 | 2 | 16115927 | ||
| Interaction | KIF5C interactions | 9.91e-07 | 88 | 18 | 4 | int:KIF5C | |
| Interaction | AZIN1 interactions | 1.05e-06 | 23 | 18 | 3 | int:AZIN1 | |
| Interaction | KIF5A interactions | 1.53e-06 | 98 | 18 | 4 | int:KIF5A | |
| Interaction | FHIP1A interactions | 3.21e-06 | 33 | 18 | 3 | int:FHIP1A | |
| Interaction | FHIP2B interactions | 3.52e-06 | 34 | 18 | 3 | int:FHIP2B | |
| Interaction | APEX1 interactions | 6.06e-06 | 1271 | 18 | 8 | int:APEX1 | |
| Interaction | MYCL interactions | 1.01e-05 | 48 | 18 | 3 | int:MYCL | |
| Interaction | FHIP2A interactions | 1.61e-05 | 56 | 18 | 3 | int:FHIP2A | |
| Interaction | KPTN interactions | 1.98e-05 | 60 | 18 | 3 | int:KPTN | |
| Interaction | TRAK2 interactions | 2.19e-05 | 62 | 18 | 3 | int:TRAK2 | |
| Interaction | RUNDC3A interactions | 2.30e-05 | 63 | 18 | 3 | int:RUNDC3A | |
| Interaction | KLC1 interactions | 6.66e-05 | 255 | 18 | 4 | int:KLC1 | |
| Interaction | NUP62 interactions | 8.68e-05 | 273 | 18 | 4 | int:NUP62 | |
| Interaction | SYNE4 interactions | 9.44e-05 | 101 | 18 | 3 | int:SYNE4 | |
| Interaction | LMTK2 interactions | 1.09e-04 | 106 | 18 | 3 | int:LMTK2 | |
| Interaction | KLC3 interactions | 1.22e-04 | 110 | 18 | 3 | int:KLC3 | |
| Interaction | EP300 interactions | 1.24e-04 | 1401 | 18 | 7 | int:EP300 | |
| Interaction | CLSTN1 interactions | 1.35e-04 | 114 | 18 | 3 | int:CLSTN1 | |
| Interaction | KLC4 interactions | 1.78e-04 | 125 | 18 | 3 | int:KLC4 | |
| Interaction | IL7R interactions | 2.53e-04 | 141 | 18 | 3 | int:IL7R | |
| Interaction | ARHGEF9 interactions | 2.61e-04 | 27 | 18 | 2 | int:ARHGEF9 | |
| Interaction | PARD6B interactions | 2.81e-04 | 146 | 18 | 3 | int:PARD6B | |
| Interaction | YWHAQ interactions | 3.00e-04 | 1118 | 18 | 6 | int:YWHAQ | |
| Interaction | CLIP2 interactions | 3.02e-04 | 29 | 18 | 2 | int:CLIP2 | |
| Interaction | GPSM2 interactions | 3.45e-04 | 31 | 18 | 2 | int:GPSM2 | |
| Interaction | PRLR interactions | 3.45e-04 | 31 | 18 | 2 | int:PRLR | |
| Interaction | MCMBP interactions | 3.47e-04 | 157 | 18 | 3 | int:MCMBP | |
| Interaction | PTPN23 interactions | 3.81e-04 | 162 | 18 | 3 | int:PTPN23 | |
| Interaction | STAP2 interactions | 3.91e-04 | 33 | 18 | 2 | int:STAP2 | |
| Interaction | COG6 interactions | 3.95e-04 | 164 | 18 | 3 | int:COG6 | |
| Interaction | REPS2 interactions | 4.16e-04 | 34 | 18 | 2 | int:REPS2 | |
| Interaction | S100A2 interactions | 4.20e-04 | 412 | 18 | 4 | int:S100A2 | |
| Interaction | NAA10 interactions | 4.23e-04 | 168 | 18 | 3 | int:NAA10 | |
| Interaction | KLC2 interactions | 4.54e-04 | 172 | 18 | 3 | int:KLC2 | |
| Interaction | IL2RB interactions | 4.66e-04 | 36 | 18 | 2 | int:IL2RB | |
| Interaction | RUSC2 interactions | 5.20e-04 | 38 | 18 | 2 | int:RUSC2 | |
| Interaction | CPAP interactions | 5.35e-04 | 182 | 18 | 3 | int:CPAP | |
| Interaction | CEP43 interactions | 6.06e-04 | 190 | 18 | 3 | int:CEP43 | |
| Interaction | RBMX interactions | 6.41e-04 | 461 | 18 | 4 | int:RBMX | |
| Interaction | ARMC5 interactions | 7.14e-04 | 201 | 18 | 3 | int:ARMC5 | |
| Interaction | LRRC31 interactions | 7.56e-04 | 205 | 18 | 3 | int:LRRC31 | |
| Interaction | CCR5 interactions | 8.64e-04 | 49 | 18 | 2 | int:CCR5 | |
| Interaction | EPOR interactions | 9.00e-04 | 50 | 18 | 2 | int:EPOR | |
| Interaction | GHR interactions | 9.36e-04 | 51 | 18 | 2 | int:GHR | |
| Interaction | KIF2B interactions | 9.73e-04 | 52 | 18 | 2 | int:KIF2B | |
| Interaction | BFSP1 interactions | 9.73e-04 | 52 | 18 | 2 | int:BFSP1 | |
| Interaction | IL2RA interactions | 1.05e-03 | 54 | 18 | 2 | int:IL2RA | |
| Interaction | CD247 interactions | 1.09e-03 | 55 | 18 | 2 | int:CD247 | |
| Interaction | ANAPC2 interactions | 1.11e-03 | 234 | 18 | 3 | int:ANAPC2 | |
| Interaction | AP1B1 interactions | 1.15e-03 | 237 | 18 | 3 | int:AP1B1 | |
| Interaction | CEBPB interactions | 1.17e-03 | 1443 | 18 | 6 | int:CEBPB | |
| Interaction | HOOK1 interactions | 1.19e-03 | 240 | 18 | 3 | int:HOOK1 | |
| Interaction | MAPK8IP1 interactions | 1.21e-03 | 58 | 18 | 2 | int:MAPK8IP1 | |
| Interaction | SCOC interactions | 1.25e-03 | 59 | 18 | 2 | int:SCOC | |
| Interaction | CROCC interactions | 1.25e-03 | 59 | 18 | 2 | int:CROCC | |
| Interaction | ROPN1 interactions | 1.34e-03 | 61 | 18 | 2 | int:ROPN1 | |
| Interaction | HSPA4L interactions | 1.34e-03 | 250 | 18 | 3 | int:HSPA4L | |
| Interaction | NAA40 interactions | 1.34e-03 | 978 | 18 | 5 | int:NAA40 | |
| Interaction | PRPS2 interactions | 1.39e-03 | 253 | 18 | 3 | int:PRPS2 | |
| Interaction | NECAP2 interactions | 1.42e-03 | 63 | 18 | 2 | int:NECAP2 | |
| Interaction | FCHSD2 interactions | 1.52e-03 | 65 | 18 | 2 | int:FCHSD2 | |
| Interaction | YWHAB interactions | 1.58e-03 | 1014 | 18 | 5 | int:YWHAB | |
| Interaction | MAPK8IP3 interactions | 1.76e-03 | 70 | 18 | 2 | int:MAPK8IP3 | |
| Interaction | S100P interactions | 1.84e-03 | 279 | 18 | 3 | int:S100P | |
| Interaction | PPP4R3B interactions | 1.86e-03 | 72 | 18 | 2 | int:PPP4R3B | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr11q13 | 2.59e-05 | 454 | 18 | 4 | chr11q13 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr17q21 | 7.90e-04 | 473 | 18 | 3 | chr17q21 | |
| Cytoband | 17q11.2 | 8.49e-04 | 110 | 18 | 2 | 17q11.2 | |
| Cytoband | 11q13 | 9.76e-04 | 118 | 18 | 2 | 11q13 | |
| GeneFamily | Tetratricopeptide repeat domain containing|Bardet-Biedl syndrome associated|BBSome | 2.05e-05 | 115 | 9 | 3 | 769 | |
| GeneFamily | Pleckstrin homology domain containing|Rho guanine nucleotide exchange factors|C2 domain containing | 4.65e-04 | 66 | 9 | 2 | 722 | |
| GeneFamily | SH2 domain containing | 1.08e-03 | 101 | 9 | 2 | 741 | |
| Coexpression | GSE35685_CD34POS_CD38NEG_VS_CD34POS_CD10NEG_CD62LPOS_BONE_MARROW_DN | 9.26e-06 | 200 | 18 | 4 | M9084 | |
| ToppCell | E16.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-SCMF|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 4.52e-05 | 175 | 18 | 3 | 427a7ee92fe16a90625946492062d37aa0f7235b | |
| ToppCell | E16.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-SCMF-SCMF_mature|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 4.52e-05 | 175 | 18 | 3 | 1d8aab491dcc27ea5dbfb6462d18ee280b21a05e | |
| ToppCell | PCW_05-06-Epithelial-Epithelial_alveolar-distal-epi_SOX9^high_Etv5^high_distal_(10)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 5.25e-05 | 184 | 18 | 3 | fa4915b0498f3069fd5ef497286445528f75187e | |
| ToppCell | facs-Lung-24m-Hematologic-myeloid-myeloid_dendritic_cell-Ccr7+_dendritic|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 5.33e-05 | 185 | 18 | 3 | 19fa853f6f746ccf232a343b3c9c7a5e55800409 | |
| ToppCell | PCW_13-14-Epithelial-Epithelial_alveolar-distal-epi_SOX9^high_Etv5^high_distal_(10)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 5.42e-05 | 186 | 18 | 3 | bb0bfe9a015151be08a6ffc5d82896d0556d76de | |
| ToppCell | PCW_10-12-Epithelial-Epithelial_alveolar-distal-epi_SOX9^high_Etv5^high_distal_(10)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 5.51e-05 | 187 | 18 | 3 | db2974e2e87ac9f1c2407a371d5ed89af09fc9b7 | |
| ToppCell | PCW_13-14-Epithelial-Epithelial_alveolar-distal-epi_SFTPC^high_distal_(9)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 6.14e-05 | 194 | 18 | 3 | c47fc3f716ab091a39c20d7639ac783029589ee5 | |
| ToppCell | PCW_10-12-Epithelial-Epithelial_alveolar-distal-epi_SOX9^high_Etv5^medium_distal_(2)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 6.24e-05 | 195 | 18 | 3 | f08e41706680881ebd0afcd08a02f8ac0089f04e | |
| ToppCell | PCW_13-14-Epithelial-Epithelial_alveolar-distal-epi_SOX9^high_Etv5^medium_distal_(2)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 6.43e-05 | 197 | 18 | 3 | 2f91b3870a7058168093a143110954c07588cfe9 | |
| ToppCell | PCW_13-14-Epithelial-Epithelial_alveolar-distal|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 6.43e-05 | 197 | 18 | 3 | 6852a8ec1397811bbdd1fc625c52ed4fa75a931e | |
| ToppCell | Fetal_brain-organoid_Tanaka_cellReport-GW19-Neuroepithelial-Proteoglycan-expressing_cell|GW19 / Sample Type, Dataset, Time_group, and Cell type. | 6.72e-05 | 200 | 18 | 3 | aafe594c88710f8c53d59667cdac5035e08f5511 | |
| ToppCell | Fetal_brain-organoid_Tanaka_cellReport-GW19-Neuroepithelial|GW19 / Sample Type, Dataset, Time_group, and Cell type. | 6.72e-05 | 200 | 18 | 3 | a6f0f5f644b7262878b0b9d4d90ee407c4124dd9 | |
| ToppCell | 390C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_4|CD8+_Cytotoxic_T-cell / Donor, Lineage, Cell class and subclass (all cells) | 6.60e-04 | 95 | 18 | 2 | 3d6b97576ce4e7a3e495cbc7246ea8c0b2a386f7 | |
| ToppCell | saliva-Severe-critical_progression_d12-22_with-steroid-Myeloid-Monocytic-Classical_Monocyte-Mono_c3-CD14-VCAN|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 7.17e-04 | 99 | 18 | 2 | a815a887094204de30b299e8907e81ad9a39c016 | |
| ToppCell | LPS-IL1RA-Epithelial_alveolar-Mes-Like-AT2_Progenitor|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 8.06e-04 | 105 | 18 | 2 | 9ed5482b445eacf16d5769f79438098b0e71123a | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT1|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.23e-03 | 130 | 18 | 2 | 6434d9106ccb38786dad36fab80163dfc07b6eb7 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c03-ITGA4|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.32e-03 | 135 | 18 | 2 | 0e5dfbe79598fc7822a7b3baa8d7dba3c9da1dad | |
| ToppCell | metastatic_Lymph_Node-Myeloid_cells-Alveolar_Mac|Myeloid_cells / Location, Cell class and cell subclass | 1.44e-03 | 141 | 18 | 2 | 399380de5ea09e22fd128e3e55fffeffc4874c15 | |
| ToppCell | Mild/Remission-B_naive-5|World / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 1.46e-03 | 142 | 18 | 2 | fc5fc2d2b4b976358b8ce762c1f440b20db84103 | |
| ToppCell | Mild/Remission-B_naive-5|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 1.59e-03 | 148 | 18 | 2 | 8b60f9843505660b3c9d5c7792976f902be4b94c | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Immune-Myeloid-Granulocytic|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 1.70e-03 | 153 | 18 | 2 | 83942ef63d21725fa15ed5a91481d1f9936e8f11 | |
| ToppCell | 356C-Fibroblasts-Fibroblast-B_(Myofibroblast)-|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells) | 1.78e-03 | 157 | 18 | 2 | 43a6b423fd70479822a564ff4225a1e4951ae5ed | |
| ToppCell | 10x3'2.3-week_12-13-Hematopoietic-HSC/MPP_and_pro-pDC_progenitor|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 1.78e-03 | 157 | 18 | 2 | 62f029831c420d3e9580822177545eb7fdf4d0a3 | |
| ToppCell | 356C-Fibroblasts-Fibroblast-B_(Myofibroblast)|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells) | 1.78e-03 | 157 | 18 | 2 | f6210be2362d833c6d869ff921188bfc85dda11d | |
| ToppCell | TCGA-Bladder-Primary_Tumor-Urothelial_Carcinoma-Papillary_Muscle_Invasive_Urothelial_Carcinoma|TCGA-Bladder / Sample_Type by Project: Shred V9 | 1.81e-03 | 158 | 18 | 2 | dc559503bab3ec1b9ea54ef2e896d1be33e5344c | |
| ToppCell | droplet-Kidney-KIDNEY-30m-Lymphocytic-Epcam____proximal_tube_epithelial_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.81e-03 | 158 | 18 | 2 | 1d78578dc1f8ba43dacdccae1082c0b9d749f64d | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Neural-neural_cell-Schwann_Cell_/_Neural|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.85e-03 | 160 | 18 | 2 | 14dfa519e68bab4bce890ddb66fa7763f18d9f19 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Neural|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.85e-03 | 160 | 18 | 2 | 5b7789d4668ed7732babedc32d812233b430e0bd | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Immune-Myeloid-Granulocytic-Mast_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 1.85e-03 | 160 | 18 | 2 | fe9970c160159b35f6599ed13c89cfb49264d554 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Neural-neural_cell-Schwann_Cell_/_Neural-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.85e-03 | 160 | 18 | 2 | bba1486faaad5299e10f4fe17c6d149c28dc2560 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Neural-neural_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.85e-03 | 160 | 18 | 2 | 839bbdfd4e4c7b48260c8bfb7670378634405e1d | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Immune-Myeloid-Granulocytic-Mast_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 1.88e-03 | 161 | 18 | 2 | c54010d88f1ecb6e0235bb66084876a4d5bf1ecd | |
| ToppCell | E16.5-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT1/AT2|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.94e-03 | 164 | 18 | 2 | b6beb8548ac0dd07e8a580a938e5ee4bf25a3c1f | |
| ToppCell | 3'-GW_trimst-1-LargeIntestine-Hematopoietic-B_cells-CLP|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.94e-03 | 164 | 18 | 2 | f5cacd7b2329cb0c7c1696eb4d8f89a4bbd9dda1 | |
| ToppCell | E16.5-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT1/AT2-AT1/AT2_mature|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.94e-03 | 164 | 18 | 2 | fe11fcce4ba7f44ba2989ea3705916b67e75f8e7 | |
| ToppCell | P28-Epithelial-airway_epithelial_cell-ciliated_cell_of_airway|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 2.04e-03 | 168 | 18 | 2 | 8c8dbdbc7053f34e4ca0c5067af502fbea109fc1 | |
| ToppCell | 343B-Epithelial_cells-Epithelial-J_(AT1-AT2_progenitors)-|343B / Donor, Lineage, Cell class and subclass (all cells) | 2.06e-03 | 169 | 18 | 2 | a949f547b53126a208819bade74a1ac9b2a36ea7 | |
| ToppCell | 343B-Epithelial_cells-Epithelial-J_(AT1-AT2_progenitors)|343B / Donor, Lineage, Cell class and subclass (all cells) | 2.06e-03 | 169 | 18 | 2 | 195d5cd60d646ac6d40a3321b2f739917e7aef14 | |
| ToppCell | droplet-Marrow-nan-3m-Myeloid-basophil|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.06e-03 | 169 | 18 | 2 | 5f5bec13208f4c3b6eacbba180c8a6402743b76e | |
| ToppCell | droplet-Skin-nan-18m-Epithelial-keratinocyte_stem_cell|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.09e-03 | 170 | 18 | 2 | 10e0912dd0beab5d0bbe2bd49e477b5962687925 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Vascular-Mural_cell-Pericyte-B|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 2.11e-03 | 171 | 18 | 2 | a4a2c5dc995589fbe3d4ca6ee1df888807e4ae34 | |
| ToppCell | 3'_v3-GI_small-bowel-Mast-Mast_cell_granulo-myelo|GI_small-bowel / Manually curated celltypes from each tissue | 2.14e-03 | 172 | 18 | 2 | 3df11aefc09762fd1f94441324551178e030b249 | |
| ToppCell | LV-11._Adipocyte|LV / Chamber and Cluster_Paper | 2.16e-03 | 173 | 18 | 2 | c2d3fcb3de71015d03d14c63450853d2b03ffa71 | |
| ToppCell | Adult-Epithelial-lung_goblet_cell-D231|Adult / Lineage, Cell type, age group and donor | 2.18e-03 | 174 | 18 | 2 | 7d2f802f493f19a068e097b2909a9000e2160266 | |
| ToppCell | 10x3'2.3-week_17-19-Lymphocytic_T-T_NK-CD8_T_cell|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 2.18e-03 | 174 | 18 | 2 | fee2ee3e888ce71f9f3f05d7dc8aaa9549480205 | |
| ToppCell | droplet-Lung-LUNG-30m-Myeloid-Ccr7+_Dendritic|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.21e-03 | 175 | 18 | 2 | 91cb819a1786020713b7e64480de0545380daae9 | |
| ToppCell | pdx-Tumor_cells-T2|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells) | 2.23e-03 | 176 | 18 | 2 | 1e21f80cf0e695ffdd63e4a72cf1e3fa41b60341 | |
| ToppCell | kidney_cells-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.23e-03 | 176 | 18 | 2 | 66c9c6b59030f67e8d746a9c6930e50923f2ded1 | |
| ToppCell | kidney_cells-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.23e-03 | 176 | 18 | 2 | b4a23d8d1414434adeb237a96f28c825f1aebd77 | |
| ToppCell | facs-Lung-nan-3m-Epithelial-Club_Cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.26e-03 | 177 | 18 | 2 | b37d821f4f3204daf7c568ac17a0af0ba97273d6 | |
| ToppCell | facs-BAT-Fat-3m-Epithelial-nan|BAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.26e-03 | 177 | 18 | 2 | 7480e522cfae3f5c6c62720083750f8273725ab5 | |
| ToppCell | facs-BAT-Fat-3m-Epithelial|BAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.26e-03 | 177 | 18 | 2 | 3e42f6236962dd9bb23dc0d09b460ec8347d1056 | |
| ToppCell | facs-Lung-nan-3m-Epithelial-club_cell_of_bronchiole|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.26e-03 | 177 | 18 | 2 | e5070934c674a46e070b0d52b9a374516bf6aea1 | |
| ToppCell | facs-BAT-Fat-3m-Epithelial-epithelial_cell|BAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.26e-03 | 177 | 18 | 2 | 128186bc996784e670194c07c5352e69af5f6d68 | |
| ToppCell | droplet-Marrow-BM_(NON-STC)-30m-Lymphocytic-naive_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.26e-03 | 177 | 18 | 2 | 9b4c1ca5c6fca9a7a936dad49a04155903ef9c32 | |
| ToppCell | 356C-Lymphocytic-CD4_T-cell-Treg_cell_1|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells) | 2.26e-03 | 177 | 18 | 2 | 36b5d29caa9cffbc0284f771a4db71aa72171a89 | |
| ToppCell | 3'-GW_trimst-2-LargeIntestine-Mesenchymal-Pericytes-Immature_pericyte|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.28e-03 | 178 | 18 | 2 | e5e4742e35c3d90f82b830d77bdbdc45828c7deb | |
| ToppCell | 390C-Lymphocytic-CD4_T-cell-Treg_cell_2|390C / Donor, Lineage, Cell class and subclass (all cells) | 2.28e-03 | 178 | 18 | 2 | 829ea00c022a78d1861aa3ec53503272976775d9 | |
| ToppCell | droplet-Kidney-KIDNEY-30m-Lymphocytic-Epcam____thick_ascending_tube_S_epithelial_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.31e-03 | 179 | 18 | 2 | 4166c4e1a8748a79ac6a11fd0b97c5344be2321b | |
| ToppCell | facs-Lung-EPCAM-24m-Myeloid-Ccr7+_Dendritic|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.31e-03 | 179 | 18 | 2 | 1b979e0203a2ddfe98bf6c2c80c4af1ba437a80f | |
| ToppCell | facs-Lung-EPCAM-24m-Myeloid-dendritic_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.31e-03 | 179 | 18 | 2 | 51872338e54c5f3e42ca9f1c4cf1e8b0cb84afcc | |
| ToppCell | Adult-Epithelial-lung_goblet_cell|Adult / Lineage, Cell type, age group and donor | 2.31e-03 | 179 | 18 | 2 | 1fc1f252ca943a2f649d1e627f56acbf15f8e058 | |
| ToppCell | 10x5'-lymph-node_spleen-Myeloid_Mac-Intestinal_macrophages|lymph-node_spleen / Manually curated celltypes from each tissue | 2.33e-03 | 180 | 18 | 2 | 7be7d7a6906fff6dbdecd9cb013d855aba4eda2a | |
| ToppCell | 10x5'v1-week_17-19-Myeloid_macrophage-stroma-monocytoid_macrophage|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 2.33e-03 | 180 | 18 | 2 | ba4c1fb55e8f1095bea6968417fefcf5f700926b | |
| ToppCell | 356C-Lymphocytic-CD4_T-cell-Treg_cell_1|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 2.33e-03 | 180 | 18 | 2 | a682a5d55c612709c9ee9fa4289d6f8bef7fe1af | |
| ToppCell | facs-Lung-3m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l17|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 2.33e-03 | 180 | 18 | 2 | 39ae8586efd91536e9ac6408d26de7e6d6237c41 | |
| ToppCell | 390C-Lymphocytic-CD4_T-cell-Treg_cell_2|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 2.36e-03 | 181 | 18 | 2 | 9275531e896e118cee043ed94fd31a0070d9581c | |
| ToppCell | Leuk-UTI-Lymphocyte-T_NK-CD8_Naive|Leuk-UTI / Disease, Lineage and Cell Type | 2.39e-03 | 182 | 18 | 2 | 3500a826d86beb98980e2b24e074b02e8e2f957e | |
| ToppCell | facs-Lung-Endomucin-24m-Mesenchymal-Pericyte|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.39e-03 | 182 | 18 | 2 | 74dbb706bcaa0f8c922bf3b0424bce5bb27167fa | |
| ToppCell | TCGA-Mesothelium-Primary_Tumor-Mesothelioma-Epitheliod|TCGA-Mesothelium / Sample_Type by Project: Shred V9 | 2.39e-03 | 182 | 18 | 2 | bb1f815718397de96682697fcbd6014a992a28f7 | |
| ToppCell | facs-Lung-Endomucin-24m-Mesenchymal-pericyte_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.39e-03 | 182 | 18 | 2 | be9c312a44868d4ee266a64d066feb8c5bce5687 | |
| ToppCell | tumor_Lymph_Node_/_Brain-Myeloid_cells-Alveolar_Mac|Myeloid_cells / Location, Cell class and cell subclass | 2.39e-03 | 182 | 18 | 2 | a035d45fd512bee8dac38eb387dbf39f5a8a1fed | |
| ToppCell | E18.5-samps-Mesenchymal-Myofibroblast|E18.5-samps / Age Group, Lineage, Cell class and subclass | 2.41e-03 | 183 | 18 | 2 | de08f9ea02b7244d5a8788064631d10f06565337 | |
| ToppCell | Control-Epithelial_cells-Airway_mucous|Control / group, cell type (main and fine annotations) | 2.41e-03 | 183 | 18 | 2 | 15d24a4fb1ffe6cbafbd54fcd7dde9ddcfbe03b2 | |
| ToppCell | PCW_05-06-Epithelial-Epithelial_airway-epi_proximal_progenitor1_(6)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 2.41e-03 | 183 | 18 | 2 | c5b10571599dc26476170b54b53f09c23e6b3117 | |
| ToppCell | 3'-Child04-06-SmallIntestine-Mesenchymal-fibroblastic-Stromal_4_(MMP1+)|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.41e-03 | 183 | 18 | 2 | 269afec240a756eec3bbae5f30ec784281af3433 | |
| ToppCell | RA-13._Vascular_Smooth_Muscle|World / Chamber and Cluster_Paper | 2.41e-03 | 183 | 18 | 2 | cae2ee08f985a6f005b4b8e959e465350315156a | |
| ToppCell | Control-Epithelial_cells-Airway_goblet|Control / group, cell type (main and fine annotations) | 2.44e-03 | 184 | 18 | 2 | d92a71441e4e19f8c301999d8186f8e48e3cd162 | |
| ToppCell | Children_(3_yrs)-Immune-interstitial_macrophage_(C1Q_positive)-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 2.46e-03 | 185 | 18 | 2 | 8207f9eff113eed429e961748c6b17d672a13b33 | |
| ToppCell | Adult-Immune-interstitial_macrophage_(C1Q_positive)-D175|Adult / Lineage, Cell type, age group and donor | 2.46e-03 | 185 | 18 | 2 | ab5704b96f1d368911308797d10c7c52766ab134 | |
| ToppCell | 343B-Fibroblasts-Fibroblast-E|343B / Donor, Lineage, Cell class and subclass (all cells) | 2.49e-03 | 186 | 18 | 2 | 59db239f1864a5d4f1570c93219dbd7ac5b6db35 | |
| ToppCell | droplet-Lung-21m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l1|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 2.49e-03 | 186 | 18 | 2 | 7c1807fca590cdccf7f5734460bac228d33964ca | |
| ToppCell | LPS-IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.49e-03 | 186 | 18 | 2 | 4e94158db52df41d71e67b02b9895a358eebee0f | |
| ToppCell | 390C-Lymphocytic-CD4_T-cell-Treg_cell_1|390C / Donor, Lineage, Cell class and subclass (all cells) | 2.49e-03 | 186 | 18 | 2 | 064b6047215597465bb51a8a1547ef5a226552f9 | |
| ToppCell | 343B-Fibroblasts-Fibroblast-E-|343B / Donor, Lineage, Cell class and subclass (all cells) | 2.49e-03 | 186 | 18 | 2 | 1bac7825c2fe3e6cdff65026b09b9ccaa40fa27f | |
| ToppCell | 5'-GW_trimst-2-LargeIntestine-Mesenchymal-Pericytes-Immature_pericyte|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.49e-03 | 186 | 18 | 2 | 6568358812f0ca4e0161a1a1b29682fbced35c79 | |
| ToppCell | Control-Lymphocyte-T_NK-CD8_Naive|Control / Disease, Lineage and Cell Type | 2.52e-03 | 187 | 18 | 2 | cf8bebef36e1ec76a22f229e5c073b3a201d1b93 | |
| ToppCell | LPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.52e-03 | 187 | 18 | 2 | 58d48128547ee3513d0bf7f78e61b76b1c472ca9 | |
| ToppCell | 3'_v3-lymph-node_spleen-Hematopoietic_progenitors-Cycling_pre-Myeloid-2|lymph-node_spleen / Manually curated celltypes from each tissue | 2.52e-03 | 187 | 18 | 2 | 3c10b8501226c69d71bcd99dc1c064a3c2154f87 | |
| ToppCell | ILEUM-inflamed-(3)_MNP-(3)_moDC|(3)_MNP / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 2.52e-03 | 187 | 18 | 2 | 0099def970fbc828756fbf853eca2ce77b8cd342 | |
| ToppCell | Fetal_29-31_weeks-Immune-interstitial_macrophage_(C1Q_positive)-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 2.54e-03 | 188 | 18 | 2 | 3be2d50148daa4eddddc2c7f269f45c97f7e4931 | |
| ToppCell | PCW_05-06-Endothelial-Endothelial_immature-endo_immature4_(5)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 2.54e-03 | 188 | 18 | 2 | b9c5d573fc5ab0f7f38c55d006f9576634b05462 | |
| ToppCell | 5'-Airway_Nasal-Immune_Myeloid_mast-Myeloid_Mast/Baso-mast_cell-Mast_cells-Mast_cells_L.1.4.0.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.57e-03 | 189 | 18 | 2 | aba941ba6ce7702418b3f470bde573d123c4aade | |
| ToppCell | PCW_07-8.5-Epithelial-Epithelial_airway-epi_proximal_progenitor1_(6)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 2.57e-03 | 189 | 18 | 2 | 7659c7bbd58ee959a159294fb8d17317bbcc5681 | |
| ToppCell | normal_Lung-MAST_cells-MAST|normal_Lung / Location, Cell class and cell subclass | 2.57e-03 | 189 | 18 | 2 | fd053209034fca6eaefe0e5ad024ac4548a100c9 | |
| ToppCell | 390C-Myeloid-Macrophage-FABP4+_Macrophage_2|390C / Donor, Lineage, Cell class and subclass (all cells) | 2.57e-03 | 189 | 18 | 2 | 3b5e1a8d5c1e1fa2124f64f212e9c6b8f1b7d7da | |
| ToppCell | 3'-Parenchyma_lung-Immune_Myeloid_mast-Myeloid_Mast/Baso-mast_cell-Mast_cells-Mast_cells_L.1.4.1.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.57e-03 | 189 | 18 | 2 | d26af19fd7e0c7eb78a5a3a245ca5229c4e9e847 | |
| ToppCell | COVID-19-Heart-Macrophage|COVID-19 / Disease (COVID-19 only), tissue and cell type | 2.57e-03 | 189 | 18 | 2 | 2586f4088721c5debec86c2b211b739fd33713eb | |
| ToppCell | normal_Lung-MAST_cells|normal_Lung / Location, Cell class and cell subclass | 2.57e-03 | 189 | 18 | 2 | f09e387dc0626536050cd537dda212471a7267c4 | |
| ToppCell | CTRL-Lymphoid-B_cell|Lymphoid / Disease state, Lineage and Cell class | 2.57e-03 | 189 | 18 | 2 | 14f3a8c0f4f057ad4e6839b4c3eeaf956d6dc92e | |
| Drug | Dicyclomine hydrochloride [67-92-5]; Up 200; 11.6uM; PC3; HG-U133A | 3.70e-07 | 198 | 18 | 5 | 1902_UP | |
| Drug | AZD 1480 | 3.54e-06 | 4 | 18 | 2 | ctd:C545606 | |
| Drug | 2-hydroxy-1-(2-((9-(4-methylcyclohexyl)-9H-pyrido(4',3'-4,5)pyrrolo(2,3-d)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)ethanone | 8.84e-06 | 6 | 18 | 2 | ctd:C000589290 | |
| Drug | N'-(11H-indolo(3,2-c)quinolin-6-yl)-N,N-dimethylethane-1,2-diamine | 2.65e-05 | 10 | 18 | 2 | ctd:C524250 | |
| Drug | 2,4-dihydroxy-N-(4-hydroxyphenyl)benzamide | 2.65e-05 | 10 | 18 | 2 | ctd:C585912 | |
| Drug | Trapoxin B | 3.16e-05 | 79 | 18 | 3 | CID000005532 | |
| Drug | Organothiophosphates | 3.23e-05 | 11 | 18 | 2 | ctd:D063086 | |
| Drug | AC1L1BB2 | 3.66e-05 | 83 | 18 | 3 | CID000001361 | |
| Drug | boron | 4.28e-05 | 257 | 18 | 4 | CID005462311 | |
| Drug | quizartinib | 4.58e-05 | 13 | 18 | 2 | ctd:C544967 | |
| Drug | benzo(a)pyrene-1,6-quinone | 7.97e-05 | 17 | 18 | 2 | ctd:C030233 | |
| Drug | benzo(a)pyrene-3,6-quinone | 8.96e-05 | 18 | 18 | 2 | ctd:C018003 | |
| Drug | triphenylmethane | 1.23e-04 | 21 | 18 | 2 | CID000010614 | |
| Drug | AC1L1DKK | 1.30e-04 | 127 | 18 | 3 | CID000002390 | |
| Drug | BP-1,6-quinone | 1.35e-04 | 22 | 18 | 2 | CID000018300 | |
| Drug | tubulin polymerization inhibitor | 1.81e-04 | 142 | 18 | 3 | CID010125800 | |
| Drug | A19457 | 2.09e-04 | 149 | 18 | 3 | CID000004042 | |
| Drug | HMBA | 2.43e-04 | 157 | 18 | 3 | CID000003616 | |
| Drug | PCB 28 | 2.53e-04 | 30 | 18 | 2 | CID000023448 | |
| Drug | Methylene Chloride | 2.72e-04 | 163 | 18 | 3 | ctd:D008752 | |
| Drug | norcantharidin | 3.07e-04 | 33 | 18 | 2 | ctd:C069741 | |
| Drug | brequinar | 3.26e-04 | 34 | 18 | 2 | CID000057030 | |
| Drug | guanidinoethylmercaptosuccinic acid | 3.46e-04 | 35 | 18 | 2 | CID000003464 | |
| Drug | sauchinone | 3.46e-04 | 35 | 18 | 2 | ctd:C410958 | |
| Drug | nitroxyl | 3.94e-04 | 185 | 18 | 3 | CID000000945 | |
| Drug | Benoxinate hydrochloride [5987-82-6]; Down 200; 11.6uM; MCF7; HT_HG-U133A | 4.26e-04 | 190 | 18 | 3 | 4115_DN | |
| Drug | K-S-L | 4.30e-04 | 39 | 18 | 2 | CID000484125 | |
| Drug | N-acetylmethionine | 4.30e-04 | 39 | 18 | 2 | CID000006180 | |
| Drug | Methotrexate [59-05-2]; Up 200; 8.8uM; HL60; HG-U133A | 4.32e-04 | 191 | 18 | 3 | 2041_UP | |
| Drug | Bacampicillin hydrochloride [37661-08-8]; Up 200; 8uM; HL60; HT_HG-U133A | 4.39e-04 | 192 | 18 | 3 | 1337_UP | |
| Drug | Acacetin [480-44-4]; Down 200; 14uM; MCF7; HT_HG-U133A | 4.39e-04 | 192 | 18 | 3 | 6044_DN | |
| Drug | alpha-estradiol; Down 200; 0.01uM; MCF7; HT_HG-U133A_EA | 4.46e-04 | 193 | 18 | 3 | 1048_DN | |
| Drug | Quercetine dihydrate [6151-25-3]; Down 200; 11.8uM; MCF7; HT_HG-U133A | 4.46e-04 | 193 | 18 | 3 | 4846_DN | |
| Drug | Muramic acid, N-acetyl [10597-89-4]; Up 200; 13.6uM; MCF7; HT_HG-U133A | 4.46e-04 | 193 | 18 | 3 | 3262_UP | |
| Drug | Acetopromazine maleate salt [3598-37-6]; Down 200; 9uM; MCF7; HT_HG-U133A | 4.52e-04 | 194 | 18 | 3 | 6832_DN | |
| Drug | W-13, hydrochloride; Up 200; 10uM; MCF7; HG-U133A | 4.52e-04 | 194 | 18 | 3 | 440_UP | |
| Drug | Il 10 | 4.52e-04 | 40 | 18 | 2 | CID000146070 | |
| Drug | Naringenine [480-41-1]; Up 200; 14.6uM; MCF7; HT_HG-U133A | 4.59e-04 | 195 | 18 | 3 | 3278_UP | |
| Drug | Trioxsalen [3902-71-4]; Down 200; 17.6uM; PC3; HT_HG-U133A | 4.59e-04 | 195 | 18 | 3 | 5736_DN | |
| Drug | Amoxapine [14028-44-5]; Down 200; 12.8uM; MCF7; HT_HG-U133A | 4.59e-04 | 195 | 18 | 3 | 4996_DN | |
| Drug | Cinoxacin [28657-80-9]; Down 200; 15.2uM; PC3; HT_HG-U133A | 4.59e-04 | 195 | 18 | 3 | 5783_DN | |
| Drug | Niacin [59-67-6]; Up 200; 32.4uM; MCF7; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 5301_UP | |
| Drug | 6-Furfurylaminopurine [525-79-1]; Down 200; 18.6uM; HL60; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 2511_DN | |
| Drug | Tolazamide [1156-19-0]; Down 200; 12.8uM; HL60; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 2482_DN | |
| Drug | Norethynodrel [68-23-5]; Down 200; 13.4uM; MCF7; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 1696_DN | |
| Drug | Sulfamethoxypyridazine [80-35-3]; Up 200; 14.2uM; MCF7; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 3409_UP | |
| Drug | Trimetazidine dihydrochloride [13171-25-0]; Up 200; 11.8uM; MCF7; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 2876_UP | |
| Drug | Butirosin disulfate salt [51022-98-1]; Up 200; 5.4uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 6779_UP | |
| Drug | Riboflavine [83-88-5]; Up 200; 10.6uM; HL60; HG-U133A | 4.73e-04 | 197 | 18 | 3 | 1767_UP | |
| Drug | Hydrastine hydrochloride [5936-28-7]; Up 200; 9.6uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 2889_UP | |
| Drug | Mycophenolic acid [24280-93-1]; Down 200; 12.4uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 4137_DN | |
| Drug | Noscapine [128-62-1]; Down 200; 9.6uM; PC3; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 5851_DN | |
| Drug | Meclozine dihydrochloride [1104-22-9]; Down 200; 8.6uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 5244_DN | |
| Drug | Ethamsylate [2624-44-4]; Down 200; 15.2uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 7335_DN | |
| Drug | Cyclacillin [3485-14-1]; Down 200; 11.8uM; PC3; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 3800_DN | |
| Drug | Cinoxacin [28657-80-9]; Down 200; 15.2uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 6257_DN | |
| Drug | Lymecycline [992-21-2]; Down 200; 6.6uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 3514_DN | |
| Drug | Pimozide [2062-78-4]; Down 200; 8.6uM; PC3; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 7132_DN | |
| Drug | Iopromide [73334-07-3]; Up 200; 5uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 6842_UP | |
| Drug | Benzthiazide [91-33-8]; Up 200; 9.2uM; MCF7; HT_HG-U133A | 4.80e-04 | 198 | 18 | 3 | 3329_UP | |
| Drug | Loracarbef [121961-22-6]; Up 200; 10.8uM; MCF7; HT_HG-U133A | 4.80e-04 | 198 | 18 | 3 | 5492_UP | |
| Drug | (1-[(4-Chlorophenyl)phenyl-methyl]-4-methylpiperazine) [1620-21-9]; Down 200; 11.8uM; MCF7; HT_HG-U133A | 4.80e-04 | 198 | 18 | 3 | 4367_DN | |
| Drug | Tolnaftate [2398-96-1]; Down 200; 13uM; PC3; HG-U133A | 4.80e-04 | 198 | 18 | 3 | 1919_DN | |
| Drug | Altretamine [654-05-6]; Down 200; 19uM; MCF7; HT_HG-U133A | 4.80e-04 | 198 | 18 | 3 | 5688_DN | |
| Drug | Tyloxapol [25301-02-4]; Down 200; 4uM; MCF7; HT_HG-U133A | 4.80e-04 | 198 | 18 | 3 | 6452_DN | |
| Drug | Isoxicam [34552-84-6]; Down 200; 12uM; MCF7; HT_HG-U133A | 4.80e-04 | 198 | 18 | 3 | 7028_DN | |
| Drug | Zimelidine dihydrochloride monohydrate [61129-30-4]; Down 200; 9.8uM; PC3; HT_HG-U133A | 4.80e-04 | 198 | 18 | 3 | 4609_DN | |
| Drug | Dicumarol [66-76-2]; Down 200; 11.8uM; MCF7; HT_HG-U133A | 4.80e-04 | 198 | 18 | 3 | 3423_DN | |
| Drug | Isoxsuprine hydrochloride [579-56-6]; Up 200; 11.8uM; HL60; HG-U133A | 4.80e-04 | 198 | 18 | 3 | 1985_UP | |
| Drug | Flumethasone [2135-17-3]; Down 200; 9.8uM; MCF7; HT_HG-U133A | 4.87e-04 | 199 | 18 | 3 | 3410_DN | |
| Drug | Thioproperazine dimesylate [2347-80-0]; Down 200; 6.2uM; MCF7; HT_HG-U133A | 4.87e-04 | 199 | 18 | 3 | 6265_DN | |
| Drug | Iopanoic acid [96-83-3]; Up 200; 7uM; MCF7; HT_HG-U133A | 4.87e-04 | 199 | 18 | 3 | 5448_UP | |
| Drug | Chenodiol [474-25-9]; Down 200; 10.2uM; HL60; HT_HG-U133A | 4.87e-04 | 199 | 18 | 3 | 2402_DN | |
| Drug | chlorpromazine hydrochloride; Down 200; 1uM; HL60; HT_HG-U133A | 4.94e-04 | 200 | 18 | 3 | 2677_DN | |
| Drug | Talampicillin hydrochloride [39878-70-1]; Down 200; 7.8uM; HL60; HT_HG-U133A | 4.94e-04 | 200 | 18 | 3 | 2954_DN | |
| Drug | alpha-estradiol; Down 200; 0.01uM; HL60; HT_HG-U133A | 4.94e-04 | 200 | 18 | 3 | 2670_DN | |
| Drug | Debrisoquin sulfate [581-88-4]; Down 200; 9uM; PC3; HT_HG-U133A | 4.94e-04 | 200 | 18 | 3 | 6688_DN | |
| Drug | Promazine hydrochloride [53-60-1]; Up 200; 12.4uM; MCF7; HT_HG-U133A | 4.94e-04 | 200 | 18 | 3 | 3927_UP | |
| Drug | Dimaprit dihydrochloride [23256-33-9]; Up 200; 17uM; MCF7; HT_HG-U133A | 4.94e-04 | 200 | 18 | 3 | 7480_UP | |
| Drug | phosphotyrosine (pY | 5.16e-04 | 203 | 18 | 3 | CID000030819 | |
| Drug | Gp55 | 5.48e-04 | 44 | 18 | 2 | CID003003000 | |
| Drug | 2,4-diacetylphloroglucinol | 5.48e-04 | 44 | 18 | 2 | CID000016547 | |
| Drug | theaflavin | 6.87e-04 | 224 | 18 | 3 | CID000114777 | |
| Drug | MEHP | 7.07e-04 | 50 | 18 | 2 | CID000020393 | |
| Drug | HT-2 toxin | 7.36e-04 | 51 | 18 | 2 | CID000073050 | |
| Disease | Alzheimer's disease 1 (implicated_via_orthology) | 5.55e-09 | 7 | 17 | 3 | DOID:0080348 (implicated_via_orthology) | |
| Disease | colon adenocarcinoma (is_implicated_in) | 1.01e-04 | 26 | 17 | 2 | DOID:234 (is_implicated_in) | |
| Disease | gastric adenocarcinoma (is_marker_for) | 1.17e-04 | 28 | 17 | 2 | DOID:3717 (is_marker_for) | |
| Disease | Combined immunodeficiency | 2.53e-04 | 41 | 17 | 2 | C0494261 | |
| Disease | Acute Promyelocytic Leukemia | 3.19e-04 | 46 | 17 | 2 | C0023487 | |
| Disease | C-X-C motif chemokine 10 measurement | 1.77e-03 | 109 | 17 | 2 | EFO_0008056 | |
| Disease | breast carcinoma | 2.35e-03 | 1019 | 17 | 4 | EFO_0000305 | |
| Disease | urinary albumin to creatinine ratio | 4.69e-03 | 179 | 17 | 2 | EFO_0007778 | |
| Disease | apolipoprotein A 1 measurement | 1.19e-02 | 848 | 17 | 3 | EFO_0004614 | |
| Disease | red blood cell density measurement | 1.32e-02 | 880 | 17 | 3 | EFO_0007978 | |
| Disease | telomere length | 1.37e-02 | 313 | 17 | 2 | EFO_0004505 | |
| Disease | urate measurement | 1.38e-02 | 895 | 17 | 3 | EFO_0004531 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| EQRQCLRRLQQVLQW | 781 | Q8TER5 | |
| RLLWIGLQRQARQCQ | 81 | Q9HCU0 | |
| RVLQQLQQGDWRLQQ | 436 | Q9NSY1 | |
| DTLQLWQERERRQQQ | 406 | O75427 | |
| QRTRILQANIRWQQE | 511 | Q99743 | |
| QLQQEQRRWLRRCEQ | 1446 | Q8N1W1 | |
| RAQVRRLCQENQWLR | 106 | Q9NSK0 | |
| WEILARIQQLQRRCQ | 456 | Q3MIN7 | |
| RAQVRRLVQENQWLR | 96 | Q9H0B6 | |
| QLEWERNRRQELLNQ | 446 | Q15811 | |
| RGLALVWRRQIQQLN | 476 | Q96AY2 | |
| VWRRQIQQLNRVSLE | 481 | Q96AY2 | |
| LRAQVRRLCQENQWL | 106 | Q07866 | |
| QPQQNGRCWLNRRQI | 916 | Q93100 | |
| DWNRIAELQQRNRVC | 1916 | Q14980 | |
| RWDVLIQQATQCLNR | 476 | Q9BUJ2 | |
| LLQAWERQRQEERQQ | 386 | Q3SY00 | |
| IWQNRQQIRRAEHLC | 286 | P51692 | |
| IWQNRQQIRRAEHLC | 286 | P42229 |